Slingshot members are tracking this event:
Novartis (NVS) to submit biosimilar Adalimumab to FDA for arthritis in second half of 2017
Slingshot Insights Explained
Jan 16, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Adalimumab, Biosimilar, Fda Review